Urogen Pharma’s (URGN) “Sell (D-)” Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their sell (d-) rating on shares of Urogen Pharma (NASDAQ:URGN) in a report issued on Friday,Weiss Ratings reports.

Several other research firms have also issued reports on URGN. D. Boral Capital reissued a “buy” rating and issued a $25.00 price objective on shares of Urogen Pharma in a research report on Friday, October 3rd. Wall Street Zen lowered shares of Urogen Pharma from a “hold” rating to a “sell” rating in a research report on Saturday, October 18th. Piper Sandler started coverage on shares of Urogen Pharma in a research report on Monday, August 18th. They issued an “overweight” rating and a $36.00 price objective for the company. Finally, HC Wainwright dropped their price objective on shares of Urogen Pharma from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, August 11th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $32.00.

Urogen Pharma Stock Performance

Shares of URGN stock opened at $18.97 on Friday. Urogen Pharma has a one year low of $3.42 and a one year high of $21.71. The company has a 50 day moving average price of $18.39 and a 200 day moving average price of $14.37. The firm has a market capitalization of $877.55 million, a price-to-earnings ratio of -5.71 and a beta of 1.00.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.23). Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 164.44%.The company had revenue of $24.22 million for the quarter, compared to analyst estimates of $23.06 million. As a group, equities analysts forecast that Urogen Pharma will post -3.12 EPS for the current fiscal year.

Insider Activity

In other news, CFO Chris Degnan sold 2,203 shares of the company’s stock in a transaction on Wednesday, October 8th. The shares were sold at an average price of $16.85, for a total value of $37,120.55. Following the completion of the transaction, the chief financial officer directly owned 2,280 shares in the company, valued at approximately $38,418. This represents a 49.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Jason Drew Smith sold 1,520 shares of the company’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $19.11, for a total transaction of $29,047.20. Following the completion of the transaction, the general counsel owned 43,305 shares of the company’s stock, valued at $827,558.55. This trade represents a 3.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,594 shares of company stock worth $259,713. 4.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. CWM LLC lifted its position in shares of Urogen Pharma by 18.0% in the 3rd quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after buying an additional 650 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in shares of Urogen Pharma by 9.4% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 9,261 shares of the company’s stock worth $127,000 after buying an additional 797 shares during the last quarter. Wellington Management Group LLP lifted its position in shares of Urogen Pharma by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 148,078 shares of the company’s stock worth $1,638,000 after buying an additional 1,125 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares during the last quarter. Finally, Main Street Financial Solutions LLC lifted its position in shares of Urogen Pharma by 8.2% in the 2nd quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after buying an additional 1,968 shares during the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.